What happened with APRE today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Aprea Therapeutics seeks to treat cancer by blocking pathways that cancer cells with specific mutations rely on to survive—an approach called synthetic lethality. Most of its development effort and funding go to APR-1051 and ATRN-119, which target proteins involved in the response to DNA damage. Both remain in early clinical development. Aprea has paused enrollment in ATRN-119’s single-drug trial arms and is exploring combinations with other treatments.
Government and non-government organizations provide grants to support its research; the National Cancer Institute of the National Institutes of Health is a named funder. These grants supply most of its revenue, but stock offerings have been its main source of operating funds. Aprea has no drug-sale revenue and needs additional financing to continue development. It retains worldwide commercial rights to its candidates; future drug sales depend on successful trials and regulatory approval, followed by physician adoption and payer coverage.
Aprea relies on outside organizations to run trials and manufacture drug supplies. A single contract manufacturer currently makes the active ingredients and finished drug products, with no backup supply arrangements in place.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Aprea’s prospects hinge on clinical success for its WEE1 and ATR inhibitors against rivals including Debiopharm and Artios Pharma, neither shown in this list.
Zentalis Pharmaceuticals’ azenosertib directly challenges Aprea’s APR-1051: both are investigational cancer drugs targeting WEE1. Watch azenosertib’s clinical efficacy and safety as a competitive benchmark for APR-1051.
Acrivon Therapeutics’ ACR-2316 competes with Aprea’s APR-1051 as an investigational cancer treatment targeting WEE1. ACR-2316’s clinical progress is the part of Acrivon’s precision-medicine pipeline to watch for this rivalry.
Schrodinger, Inc.’s SGR-3515 targets WEE1/Myt1 in advanced solid tumors and competes with Aprea’s APR-1051. Watch that drug’s progress rather than software sales to drugmakers, industrial companies and research institutions, which give Schrodinger a substantial business distinct from Aprea’s cancer-drug development.
AstraZeneca’s investigational cancer drugs targeting ATR compete through the same mechanism as Aprea’s ATRN-119, but its diversified commercial drug portfolio makes its share price a less direct comparison. For Aprea, watch AstraZeneca’s ATR-drug clinical progress rather than sales of its established cancer medicines.
Bristol Myers Squibb’s BMS-986463 competes with Aprea’s APR-1051 by targeting the same cancer vulnerability differently: it degrades WEE1 rather than inhibiting it. Within Bristol Myers Squibb’s broader medicine-development and sales business, watch BMS-986463’s progress as an alternative approach to Aprea’s target.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb’s report will show whether BMS-986463, which degrades WEE1, is advancing as an alternative to Aprea Therapeutics’ WEE1 inhibitor APR-1051.
Watch BMS-986463’s clinical progress, not Bristol Myers Squibb’s overall drug sales as evidence about this rivalry. If the program advances, Aprea’s APR-1051 faces a large drugmaker pursuing the same target by a different method; limited or delayed progress would mean less immediate pressure from this approach.
AstraZeneca PLC earningsAZN
AstraZeneca’s report on its investigational ATR drugs will show whether another company is advancing against the target shared with Aprea Therapeutics’ ATRN-119.
Watch clinical progress of AstraZeneca’s investigational ATR drugs, not sales of its established cancer medicines. If those programs advance, Aprea’s ATRN-119 faces deeper same-target competition; limited or delayed progress would mean less immediate pressure, but would not settle ATRN-119’s own prospects.
Schrodinger, Inc. earningsSDGR
Schrodinger’s report on SGR-3515 will show whether its WEE1 program is advancing against Aprea Therapeutics’ competing APR-1051.
Focus on SGR-3515’s clinical progress, not Schrodinger’s software sales. Progress with signs of clinical potential would mean APR-1051 faces a more advanced rival aimed at the same target; limited or delayed progress would suggest less immediate competitive pressure, but would not establish that APR-1051 works.
Zentalis Pharmaceuticals, Inc. earningsZNTL
Zentalis’s report on azenosertib will show how its WEE1 clinical program is progressing against Aprea Therapeutics’ APR-1051.
Look at azenosertib’s efficacy and safety results. Evidence of benefit with acceptable safety would make it a stronger same-target rival to Aprea’s APR-1051; limited benefit or safety concerns would weaken that competitive case, but would not establish APR-1051’s efficacy.
Aprea Therapeutics, Inc. earningsThis company
Aprea Therapeutics has no drug-sales revenue and relies on financing and small research grants to fund development; this report will show whether clinical progress is keeping pace with cash use.
Read operating expenses and cash alongside progress in the clinical programs. Lower expenses and slower cash use while trials advance would show that current funds are supporting more development; rising costs or stalled programs would point to an earlier funding need, potentially requiring financing, shareholder dilution or cuts to development.
